Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human ...
Announcement of a podium presentation at a prestigious symposium, showcasing innovative research in cell therapy for type 1 diabetes. Presentation features promising clinical data on UP421, a novel ...
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...
Scientists from Duke-NUS Medical School and their collaborators have created one of the most comprehensive single cell maps ...
A research team at the Max Planck Institute for Chemical Ecology has successfully combined single-cell RNA sequencing (scRNA-seq) and single-cell mass spectrometry (scMS) analysis on the same plant ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback